LSL Pharma Group Announces Closing of First Tranche of Convertible Debentures Offering
The net proceeds of the Offering will be used for working capital, capital expenditures, and for general corporate purposes.
- The net proceeds of the Offering will be used for working capital, capital expenditures, and for general corporate purposes.
- The Offering was led by iA Capital Markets as sole agent and sole bookrunner (the “Agent”).
- In connection with the first tranche of the Offering, the Company paid to the Agent a cash commission of $160,510 and issued 229,300 broker warrants (the “Broker Warrants”).
- All securities issued pursuant to the Offering are subject to the applicable statutory hold period of four months and one day from November 1, 2023 (the “Initial Closing Date”).